Progesterone
DrugVaginal pessaries, 200 mg/day
Other names: Utrogestan
NCT Number: NCT00329914
The purpose of the study is to determine whether a daily dose of 200 mg progesterone administered vaginally from 20-23 to 34 weeks' gestation will reduce the rate of preterm delivery amongst twin pregnancies.
Looking for future studies?
Notify Me18 year and older
Female
Interventional
Phase 2
Graz University Hospital, Graz, Austria
Multiple gestations account for 2% of all pregnancies, but cause more than 10% of the cases of preterm delivery. Due to increasing maternal age and use of assisted reproduction the number of multiple gestations is larger than ever. If markers of preterm delivery can be identified and means of preventing preterm delivery are found, it will be possible to reduce the number of children admitted to hospital because of prematurity.
Recently, two larger randomised studies investigated the effect of progesterone in singleton pregnancies of women who had previously delivered preterm. They both found a significant reduction in the preterm delivery rate in the progesterone group compared to a placebo group.
The study will be performed as a randomized, double-blind placebo controlled study of twin pregnancies in Denmark and Austria. The women will be randomised in a 1:1 ratio to two groups (progesterone versus placebo). Randomisation will be stratified per centre and according to chorionicity, as the risk of preterm delivery is doubled in monochorionic twins compared to dichorionic twins.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Vaginal pessaries, 200 mg/day
Other names: Utrogestan
Placebo pessaries containing peanut oil
Time frame: Participants will be followed until 3 weeks after delivery
Time frame: 2 years after delivery
Time frame: Participants will be followed until 3 weeks after delivery
Time frame: Participants will be followed until 3 weeks after delivery
Time frame: Participants will be followed until 3 weeks after delivery
Time frame: Participants will be followed until 3 weeks after delivery
Rigshospitalet, Denmark
Other
Effectiveness of Vaginally Administered Progesterone to Prevent Preterm Delivery in Twin Pregnancies - A Multicentre Randomized Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03608995
Biomarkers, Female Urogenital Diseases and Pregnancy Complications
Clermont-Ferrand, France
View Trial DetailsNCT02694679
Body Temperature Changes, Diarrhea
New Haven, Connecticut, United States
View Trial DetailsNCT00340249
Female Urogenital Diseases and Pregnancy Complications, Obstetric Labor Complications
Bethesda, Maryland, United States
View Trial DetailsNCT02037334
Female Urogenital Diseases and Pregnancy Complications, Obstetric Labor Complications
Leuven, Belgium
View Trial Details